Hormone receptor-positive (HR +) breast cancer is the most common phenotype of the disease, and patients in first-line treatment are typically treated for endocrine disorders in advanced stages consisting of aromatase inhibitors or other medicines [7, 8]. The gene discussed is CYP19A1; the disease is breast cancer.